NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) — Innovation1 Biotech Inc. IVBT (“Innovation1” or the “Company”), a small molecule drug discovery company focused on the clinical development of modified Schedule 1 molecules of botanical origin, today announced the appointment of Frederick E. Pierce, II, to its Board of Directors .
Mr. Pierce is a multiple-time biotechnology entrepreneur with more than 20 years of leadership and operational experience building successful biotechnology companies. He is CEO and co-founder of Decoy Therapeutics, a pharmaceutical company that created a rapid development platform for antiviral drugs. He is also an advisor to the Healthcare and Technology Accelerator at the Consulate of Canada in Boston/Cambridge. As a board member of the Canadian Entrepreneurs of New England, he serves as Chair of the Life Sciences Leadership Council. Mr. Pierce also served as a senior advisor to Bionest Partners, which provides strategic advice to leading global pharmaceutical and biotechnology companies on matters such as market access, licensing assessment and strategy, reimbursement, drug pricing and venture capital screening assistance.
“Mr. Pierce brings a wealth of experience to our Board of Directors. His background brings a proven track record of raising capital, forging transformative strategic global alliances and working with investors to deliver successful outcomes for public and private healthcare companies,” said Jeffrey Kraws , CEO of Innovation1 Biotech. “We look forward to his contributions as we continue to unlock untapped potential and create workable solutions where current treatments are inadequate or absent.”
Prior to joining Innovation1, Mr. Pierce was President of SemBioSys Genetics. His diverse career has spanned various positions, including Investor Relations at Javelin Pharmaceuticals, where he served as Vice President. He was also Vice President of Business Development and Investor Relations before becoming CEO of GlycoGenesys, Inc. He…
